Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Genenta Science S.p.A. GNTA NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • IT • USD

SharesGrow Score
49/100
2/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Genenta Science S.p.A. (GNTA) is a Biotechnology company in the Healthcare sector, currently trading at $0.71. It has a SharesGrow Score of 46/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Valuation: GNTA trades at a trailing Price-to-Earnings (P/E) of -2 (S&P 500 average ~25).

Net income is $9M (loss), growing at -54.3%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $0 against $12M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 6.89 (strong liquidity). Debt-to-assets is 0%. Total assets: $15M.

Analyst outlook: 1 / 1 analysts rate GNTA as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 28/100 (Fail), Future 100/100 (Pass), Income ?/100 (Fail).

GNTA SharesGrow Score Overview

61/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — GNTA

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
15/100
GNTA: +0%/yr revenue is, -54.3%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet GNTA: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 6.89 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
GNTA: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
100/100
Analyst outlook: 1 / 1 analysts rate GNTA as buy (100%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range0.59-10
Volume69.62K
Avg Volume (30D)1.09M
Market Cap$13.66M
Beta (1Y)0.61
Share Statistics
EPS (TTM)-0.49
Shares Outstanding$18.27M
IPO Date2021-12-15
Employees13
CEOPierluigi Paracchi
Financial Highlights & Ratios
EBITDA$-9.72M
Net Income$-8.91M
Operating Income$-9.76M
Total Cash$12.66M
Net Debt$-4.58M
Total Assets$14.82M
Price / Earnings (P/E)-1.5
Analyst Forecast
Rating ConsensusBuy
Analysts Covering1
Buy 100% Hold 0% Sell 0%
Company Info
CountryIT
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS36870W1009

Price Chart

Track all markets on TradingView
GNTA
Genenta Science S.p.A. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
0.59 52WK RANGE 10.00

People Also View

OPT
OPT
Opthea Limited
$3.41
+1.49%
 MLYS
MLYS
Mineralys Therapeutics, Inc.
$30.42
+11.35%
 PHVS
PHVS
Pharvaris N.V.
$29.14
+1.60%
 JANX
JANX
Janux Therapeutics, Inc.
$15.04
-1.31%
 RZLT
RZLT
Rezolute, Inc.
$3.59
+1.13%
 ELYM
ELYM
Eliem Therapeutics, Inc.
$5.11
-0.97%
 MOLN
MOLN
Molecular Partners AG
$4.20
+1.45%
 ADAG
ADAG
Adagene Inc.
$3.82
+0.26%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message